Author details

Full Name

Jock K Findlay

Affiliation

ORCID

Career Start Year

1966

Papers

337

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36585738	Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer.		2022
35047406	Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment.	Frontiers in Oncology	2021
33864208	DNA repair in primordial follicle oocytes following cisplatin treatment.		2021
33023532	TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.	BMC Cancer	2020
30791462	Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.	Cancers	2019
30120061	Oocytes from stem cells.		2019
31013475	Reproductive science and the future of the planet.	Reproduction	2019
30953068	Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes.	Molecular Human Reproduction	2019
29795269	Loss of PUMA protects the ovarian reserve during DNA-damaging chemotherapy and preserves fertility.	Cell Death and Disease	2018
29393911	The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.	International Journal of Molecular Sciences	2018
29682172	Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.	Oncotarget	2018
28406185	Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling.	Scientific Reports	2017
28771225	The ovarian reserve is depleted during puberty in a hormonally driven process dependent on the pro-apoptotic protein BMF.	Cell Death and Disease	2017
27465829	Endogenous inhibins regulate steroidogenesis in mouse TM3 Leydig cells by altering SMAD2 signalling.	Molecular and Cellular Endocrinology	2016
27390927	Coalition of Oct4A and Î²1 integrins in facilitating metastasis in ovarian cancer.	BMC Cancer	2016
26917450	BCL2-modifying factor promotes germ cell loss during murine oogenesis.	Reproduction	2016
27470985	Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.	Scientific Reports	2016
26423124	How Is the Number of Primordial Follicles in the Ovarian Reserve Established?	Biology of Reproduction	2015
25500021	What is the "ovarian reserve"?	Fertility and Sterility	2015
25637623	Ovarian reserve screening: a scientific and ethical analysis.	Human Reproduction	2015
26260289	A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.	Mol Cancer	2015
24782986	Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.	Frontiers in Oncology	2014
23811037	Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.	Molecular Aspects of Medicine	2014
24859845	PUMA regulates germ cell loss and primordial follicle endowment in mice.	Reproduction	2014
24571986	Loss of the proapoptotic BH3-only protein BCL-2 modifying factor prolongs the fertile life span in female mice.	Biology of Reproduction	2014
25128652	Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFÎºB-mediated induction of MMP2.	Cancer Letters	2014
24886434	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.	BMC Cancer	2014
23537295	Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.	Molecular Cancer	2013
22887554	Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.	Journal of Cellular Biochemistry	2013
23832146	How to best preserve oocytes in female cancer patients exposed to DNA damage inducing therapeutics.	Cell Death and Differentiation	2013
23322721	Betaglycan alters NFÎºB-TGFÎ²2 cross talk to reduce survival of human granulosa tumor cells.	Molecular Endocrinology	2013
23303681	Effects of TGFbeta2 on wild-type and Tgfbr3 knockout mouse fetal testis.	Biology of Reproduction	2013
22106407	The effects of FSH and activin A on follicle development in vitro.	Reproduction	2012
22301887	The primordial follicle reserve is not renewed after chemical or Î³-irradiation mediated depletion.	Reproduction	2012
22869179	Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib.	Nature Medicine	2012
22406753	Inhibins and activins: towards the future. A tribute to the late Professor Wylie W. Vale.	Molecular and Cellular Endocrinology	2012
23000175	DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa.	Molecular Cell	2012
23056490	Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.	PLoS ONE	2012
23171809	Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary.	Journal of Ovarian Research	2012
22078189	A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, ImplanonÂ®.		2011
21347412	Estrogen-dependent gene expression in the mouse ovary.	PLoS ONE	2011
21148286	Apoptosis in the germ line.	Reproduction	2011
21618587	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.	Journal of Cellular Biochemistry	2011
20670407	Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.	Journal of Ovarian Research	2010
19696014	Fetal testis dysgenesis and compromised Leydig cell function in Tgfbr3 (beta glycan) knockout mice.	Biology of Reproduction	2010
20839084	Estrogen signaling in the regulation of female reproductive functions.	Handbook of Experimental Pharmacology	2010
20005735	Inhibins: from reproductive hormones to tumor suppressors.	Trends in Endocrinology and Metabolism	2010
20546829	The lack of estrogen and excess luteinizing hormone are responsible for the female ArKO mouse phenotype.	Molecular and Cellular Endocrinology	2010
20370691	Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.	Current Cancer Drug Targets	2010
20540986	High-temperature requirement factor A3 (Htra3): a novel serine protease and its potential role in ovarian function and ovarian cancers.	Molecular and Cellular Endocrinology	2010